Intellia Therapeutics Inc
NASDAQ:NTLA

Watchlist Manager
Intellia Therapeutics Inc Logo
Intellia Therapeutics Inc
NASDAQ:NTLA
Watchlist
Price: 12.13 USD 9.08% Market Closed
Market Cap: 1.3B USD
Have any thoughts about
Intellia Therapeutics Inc?
Write Note

Wall Street
Price Targets

NTLA Price Targets Summary
Intellia Therapeutics Inc

Wall Street analysts forecast NTLA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NTLA is 39.95 USD with a low forecast of 7.07 USD and a high forecast of 111.3 USD.

Lowest
Price Target
7.07 USD
42% Downside
Average
Price Target
39.95 USD
229% Upside
Highest
Price Target
111.3 USD
818% Upside
Intellia Therapeutics Inc Competitors:
Price Targets
PRQR
ProQR Therapeutics NV
299% Upside
TWST
Twist Bioscience Corp
34% Upside
DSGN
Design Therapeutics Inc
79% Upside
DVAX
Dynavax Technologies Corp
125% Upside
300294
China Resources Boya Bio pharmaceutical Group Co Ltd
29% Upside
ITOS
Iteos Therapeutics Inc
17% Upside
BBIO
BridgeBio Pharma Inc
33% Upside
VCYT
Veracyte Inc
58% Upside

Revenue
Forecast

Revenue Estimate
Intellia Therapeutics Inc

For the last 8 years the compound annual growth rate for Intellia Therapeutics Inc's revenue is 17%. The projected CAGR for the next 3 years is 16%.

17%
Past Growth
16%
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Intellia Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

Net Income Estimate
Intellia Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-44%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NTLA's stock price target?
Price Target
39.95 USD

According to Wall Street analysts, the average 1-year price target for NTLA is 39.95 USD with a low forecast of 7.07 USD and a high forecast of 111.3 USD.

What is Intellia Therapeutics Inc's Revenue forecast?
Projected CAGR
16%

For the last 8 years the compound annual growth rate for Intellia Therapeutics Inc's revenue is 17%. The projected CAGR for the next 3 years is 16%.

Back to Top